A radiation oncology clinician scientist devoted to building an inclusive clinical research program in an integrated academic satellite network in service to the National Cancer Institute

放射肿瘤学临床科学家致力于在为国家癌症研究所服务的综合学术卫星网络中建立包容性临床研究项目

• 批准号: 10561290
• 负责人: Stephen G Chun
• 金额: $ 8.67万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-04-01 至 2028-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10561290
• 关键词: Address; Area; Artificial Intelligence; Biological Markers; Calendar; Cancer Center; Clinical Research; Clinical Trials; Development; Doctor of Medicine; Educational workshop; Eligibility Determination; Enrollment; Exclusion Criteria; Faculty; Funding; Funding Mechanisms; Institution; Leadership; Location; Malignant Neoplasms; Malignant neoplasm of central nervous system; Minority Enrollment; Mission; National Cancer Institute; Oncology; Patients; Population Heterogeneity; Principal Investigator; Protocols documentation; Radiation; Radiation Oncology; Radiation Therapy Oncology Group; Research; Research Personnel; Role; Scientist; Services; Texas; Underrepresented Minority; Universities; Woman; career; continuing medical education; demographic disparity; ethnic diversity; health care disparity; inclusion criteria; neurocognitive test; oncology trial; participant enrollment; programs; success

Project Summary This project, proposed by clinician scientist Stephen Chun, M.D. at the University of Texas, M.D. Anderson Cancer Center (MDACC) aims to expand the National Cancer Institute (NCI)-sponsored radiation oncology trial program in the Houston Area Location (HAL) integrated academic satellites and support his national leadership efforts with the NCI-sponsored cooperative groups. Since joining the MDACC faculty, Dr. Chun has led the establishment of the HAL radiation clinical trial program and is the Director of Radiation Oncology Clinical Research for the MDACC HALs. Under his leadership, there has been an unprecedented increase (1% in 2016 to 14% in 2021) in the proportion of HAL patients enrolled on radiation clinical trials. With the NCI-sponsored cooperative groups, Dr. Chun currently serves as national Principal Investigator (PI) of a high-profile NRG Oncology analysis, study champion of NRG/Alliance A082002, MDACC institutional PI of NRG-LU005, and has been a top enroller for NRG Oncology-RTOG 1308 that was previously in jeopardy for closure due to poor accrual. To achieve NCI-funded trial objectives in the MDACC HALs, Dr. Chun will spearhead the implementation and expansion of a translational biomarker program, neurocognitive testing capabilities for NCI-sponsored central nervous system (CNS) cancer trials, and the continuing medical education program on clinical research. Dr. Chun is passionate about addressing healthcare disparities and is committed to establish a workflow to track numbers of women and underrepresented minorities enrolled on clinical trials in the HALs, and independently scrutinize patient inclusion and exclusion criteria and factors among to reduce demographic disparities. In order to develop new research capabilities, Dr. Chun will join the leadership of the Protocol in a Day Workshop, which is responsible for developing MDACC investigator-initiated radiation trials, establish the radiation clinical research program at new and planned MDACC facilities, leverage artificial intelligence to capture more patients eligible for trials, and continue to develop concepts with the NCI-sponsored cooperative groups. He will commit a minimum of 20% of his effort (2.4 calendar months) to NCI-sponsored clinical research, and MDACC is committed to support Dr. Chun’s efforts and conduct of NCI-supported clinical trials. The primary objective of his career is to prioritize and expand institutional and NCI-sponsored trials in the MDACC HALs which aligns with this R50 funding mechanism as well as with the broader mission of NCI.

项目摘要 该项目由临床科学家Stephen Chun，M.D.德克萨斯大学医学博士安德森 癌症中心（MDACC）旨在扩大国家癌症研究所（NCI）赞助的放射肿瘤学试验 休斯顿地区定位（HAL）的一个项目整合了学术卫星，并支持他的国家领导能力 与国家癌症研究所赞助的合作团体共同努力。自从加入MDACC教师，春博士领导了 HAL放射临床试验项目的建立，是放射肿瘤学临床主任 MDACC HAL的研究。在他的领导下，出现了前所未有的增长（2016年增长1% 至2021年的14%），参与放射临床试验的HAL患者比例。在国家癌症研究所赞助的 作为一个合作团体，Chun博士目前担任一个备受瞩目的NRG的国家首席研究员（PI）。 肿瘤学分析，NRG/Alliance A082002的研究冠军，NRG-LU 005的MDACC机构PI， 一直是NRG肿瘤学RTOG 1308的顶级注册者，由于不良的 权责发生制。为了在MDACC HAL中实现NCI资助的试验目标，Chun博士将带头实施 和扩大翻译生物标志物计划，神经认知测试能力，为国家癌症研究所赞助 中枢神经系统（CNS）癌症试验和临床研究的继续医学教育计划。 博士Chun热衷于解决医疗保健差距，并致力于建立一个工作流程，以跟踪 参加HAL临床试验的妇女和代表性不足的少数民族人数， 仔细审查患者入选和排除标准和因素，以减少人口统计学差异。为了 为了发展新的研究能力，Chun博士将参加为期一天的研讨会， 负责开发MDACC放射治疗仪启动的放射试验，建立放射临床 在新的和计划中的MDACC设施的研究计划，利用人工智能来捕获更多的患者 有资格进行试验，并继续与国家癌症研究所赞助的合作小组一起开发概念。即属 至少有20%的努力（2.4个日历月）用于NCI赞助的临床研究，MDACC是 致力于支持Chun博士的努力和开展NCI支持的临床试验。他的主要目标是 职业生涯是优先考虑和扩大MDACC HAL中的机构和NCI申办的试验， 这一R50筹资机制以及更广泛的NCI使命。